Formulation of pharmaceutical aerosols MCQs With Answer

Formulation of pharmaceutical aerosols MCQs With Answer is a focused review resource for B. Pharm students covering aerosol science, device engineering, and formulation strategies. This set emphasizes metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, propellants (CFCs, HFAs), particle size distribution, aerodynamic diameter, aerosolization mechanisms, deposition (impaction, sedimentation, diffusion), excipients, preservatives, and stability challenges. Questions explore suspension versus solution formulations, valve and actuator design, respiratory performance metrics like emitted dose and fine particle fraction, and quality control tests such as cascade impactor analysis. Practical aspects include compatibility, processing (micronization, milling), humidity effects, and environmental considerations.

Now let’s test your knowledge with 30 MCQs on this topic.

Q1. Which parameter best defines the likelihood of a particle depositing in the lower respiratory tract?

  • Geometric diameter
  • Shape factor
  • Aerodynamic diameter

Correct Answer: Aerodynamic diameter

Q2. Which propellant replaced CFCs in pressurized MDIs due to environmental regulations?

  • Chloroform
  • Hydrofluoroalkane (HFA)
  • Propane
  • Butane

Correct Answer: Hydrofluoroalkane (HFA)

Q3. Fine Particle Fraction (FPF) is defined as the percentage of emitted aerosol mass below which aerodynamic diameter?

  • 10 µm
  • 5 µm
  • 1 µm
  • 20 µm

Correct Answer: 5 µm

Q4. Which device typically requires the patient to generate sufficient inspiratory flow to disperse the formulation?

  • Jet nebulizer
  • Metered-dose inhaler with spacer
  • Dry powder inhaler (DPI)
  • Ultrasonic nebulizer

Correct Answer: Dry powder inhaler (DPI)

Q5. Which formulation type in MDIs is more prone to sedimentation and dose variability?

  • Solution formulation
  • Suspension formulation
  • Gaseous formulation
  • Aqueous aerosol from nebulizer

Correct Answer: Suspension formulation

Q6. Which test is commonly used to measure aerodynamic particle size distribution in regulatory testing?

  • Viscometry
  • Cascade impactor analysis
  • DSC (Differential Scanning Calorimetry)
  • UV-Vis spectrophotometry

Correct Answer: Cascade impactor analysis

Q7. What is the primary deposition mechanism for particles around 10 µm in the oropharynx?

  • Brownian diffusion
  • Gravitational sedimentation
  • Inertial impaction
  • Electrostatic attraction

Correct Answer: Inertial impaction

Q8. Which excipient in aerosol suspensions helps reduce particle aggregation and improve dispersion?

  • Suspending agents like sorbitan esters
  • Strong acids
  • Heavy metals
  • Organic dyes

Correct Answer: Suspending agents like sorbitan esters

Q9. What is the role of a metering valve in an MDI?

  • Change the color of the aerosol
  • Meter a reproducible dose per actuation
  • Increase particle density
  • Sterilize the formulation

Correct Answer: Meter a reproducible dose per actuation

Q10. Which property of DPI powders increases the risk of poor dispersibility under humid conditions?

  • Hydrophobicity
  • Low bulk density
  • Hygroscopicity
  • Low melting point

Correct Answer: Hygroscopicity

Q11. In aerosol formulation, what is the main reason for micronization of drug particles?

  • Enhance taste
  • Reduce chemical stability
  • Achieve respirable particle size for pulmonary deposition
  • Make particles visible

Correct Answer: Achieve respirable particle size for pulmonary deposition

Q12. Which nebulizer type is most suitable for heat-sensitive biologic drugs?

  • Ultrasonic nebulizer
  • Jet nebulizer
  • Vibrating mesh nebulizer
  • Pressurized MDI

Correct Answer: Vibrating mesh nebulizer

Q13. Which parameter differentiates emitted dose from delivered dose in inhaler performance?

  • Chemical potency
  • Loss in actuator or spacer and oropharyngeal deposition
  • Color change during actuation
  • Ambient light intensity

Correct Answer: Loss in actuator or spacer and oropharyngeal deposition

Q14. Which preservative commonly used in aqueous inhalation solutions has raised concerns about bronchoconstriction in sensitive patients?

  • Sodium chloride
  • Benzalkonium chloride
  • Sorbitol
  • Glycerin

Correct Answer: Benzalkonium chloride

Q15. What effect does increasing actuator orifice size generally have on plume and particle size?

  • Smaller plume, smaller particles
  • No effect on plume or particles
  • Larger plume, larger droplet size
  • Transforms aerosol into gas

Correct Answer: Larger plume, larger droplet size

Q16. Which test evaluates the uniformity of delivered doses from MDIs over repeated actuations?

  • Thermogravimetric analysis
  • Dose uniformity test
  • DSC melting point test
  • Gel electrophoresis

Correct Answer: Dose uniformity test

Q17. What is a common challenge when formulating aqueous MDIs compared to HFA formulations?

  • Greater environmental harm
  • Propellant incompatibility
  • Microbial contamination and need for preservatives
  • Excessive vapor pressure

Correct Answer: Microbial contamination and need for preservatives

Q18. Which factor most strongly influences aerosol deposition by diffusion in the alveolar region?

  • Particle aerodynamic diameter >10 µm
  • Particle density only
  • Very small particle size (<0.5 µm)
  • Color of formulation

Correct Answer: Very small particle size (<0.5 µm)

Q19. Why are spacer devices recommended with MDIs for some patients?

  • To reduce medication stability
  • To increase oropharyngeal deposition
  • To improve coordination between actuation and inhalation and reduce oropharyngeal deposition
  • To heat the aerosol

Correct Answer: To improve coordination between actuation and inhalation and reduce oropharyngeal deposition

Q20. Which material interaction is a concern for aerosol formulations stored in plastic containers?

  • Surface crystallization enhancement
  • Sorption of drug or propellant into plastic and extractables/leachables
  • Improved chemical stability always
  • Increased emitted dose exclusively

Correct Answer: Sorption of drug or propellant into plastic and extractables/leachables

Q21. What is the effect of using ethanol as a co-solvent in HFA formulations?

  • Prevents aerosolization entirely
  • Acts as a cosolvent to improve drug solubility and alter plume characteristics
  • Causes immediate precipitation of drug
  • Neutralizes propellant

Correct Answer: Acts as a cosolvent to improve drug solubility and alter plume characteristics

Q22. Which measurement quantifies particle mass reaching the lower airways in aerosol testing?

  • Fine Particle Dose (FPD)
  • Colorimetric index
  • Bulk powder density
  • Viscosity

Correct Answer: Fine Particle Dose (FPD)

Q23. In suspension MDIs, which process helps maintain content uniformity during storage?

  • Avoiding micronization
  • Using appropriate suspending agents and flocculating agents to control sedimentation
  • Removing the valve
  • Increasing particle size to millimeter range

Correct Answer: Using appropriate suspending agents and flocculating agents to control sedimentation

Q24. Which property of a spray characterizes how quickly aerosol droplets decelerate after leaving the actuator?

  • Plume geometry and velocity profile
  • Electrical conductivity
  • pH
  • Melting point

Correct Answer: Plume geometry and velocity profile

Q25. For inhaled proteins and peptides, which formulation concern is most critical?

  • Taste masking in the oropharynx
  • Chemical and physical stability (aggregation, denaturation) during aerosolization
  • High melting point
  • Color stability

Correct Answer: Chemical and physical stability (aggregation, denaturation) during aerosolization

Q26. Which device parameter is adjusted to control the metered volume in a pMDI valve system?

  • Actuator color
  • Metering chamber volume of the valve
  • Label text size
  • Ambient humidity

Correct Answer: Metering chamber volume of the valve

Q27. What is the main advantage of breath-actuated inhalers for patients?

  • They require complex priming by the user
  • They eliminate the need for coordination between actuation and inhalation
  • They always deliver larger particles
  • They are more likely to cause contamination

Correct Answer: They eliminate the need for coordination between actuation and inhalation

Q28. Which factor most reduces aerosol output from a jet nebulizer during use?

  • Low residual volume in the nebulizer cup
  • Clogged air-jet or compressed air supply issues
  • Using distilled water only
  • Increasing the drug concentration

Correct Answer: Clogged air-jet or compressed air supply issues

Q29. During DPI formulation, why are carrier particles like lactose used?

  • To chemically react with the drug
  • To improve powder flow, dispersion and aid dose metering
  • To dissolve the drug during inhalation
  • To increase hygroscopicity

Correct Answer: To improve powder flow, dispersion and aid dose metering

Q30. Which environmental concern is associated with some aerosol propellants and has driven formulation changes?

  • Increase in ambient temperature only
  • Ozone depletion and global warming potential of certain propellants
  • Increase in soil acidity
  • Excessive noise pollution

Correct Answer: Ozone depletion and global warming potential of certain propellants

Leave a Comment